Repurposing the anticancer drug cisplatin with the aim of developing novel Pseudomonas aeruginosa infection control agents

Scholarly Works

• Daghistani, H.; Attallah, D.; Alqarni, M. A.; Saleh, B. H.; Alhussainy, N. H.; Sait, A. M.; Mufrrih, M.; Alhazmi, W.; Alharbi, O. S.; Alhazmi, K. A.; Altalhi, R.; Halabi, W. S.; Almuhayya, S.; Aldehalan, F. A.; Altarawneh, H.; Abu Lubad, M.; Bani Abdel-Rahman, S. M. S.; Alfadil, A.; Ibrahem, K. Repurposing the Anticancer Drug Cisplatin for Antibacterial Therapy: Evaluating Its Efficacy Against Pseudomonas aeruginosa Infections. Infection and drug resistance 2025, 18, 4179–4186. doi:10.2147/idr.s524005
• Palit, S.; Sanapalli, B. K. R.; Manda, S. B.; Deshpande, A.; Sanapalli, V. Uncovering Hidden Antibacterial Potential: A Computational Discovery of FDA‐Approved Drugs against ThiL Enzyme. ChemistrySelect 2025, 10. doi:10.1002/slct.202501135
• Sharma, B.; Chadha, J.; Khullar, L.; Rashpa, S.; Harjai, K. FDA-approved drugs for targeting virulence of Pseudomonas aeruginosa: A drug repurposing approach to combat multidrug resistance. Microbial pathogenesis 2025, 206, 107781. doi:10.1016/j.micpath.2025.107781
• Dhariwal, R.; Upadhyay, A.; Deshmukh, K.; Patil, N.; Upadhyay, B.; Janiyani, K.; Singh, H.; Jain, M. Combinatorial Drug Therapy for <i>Salmonella</i> Biofilm Disruption. <i>Salmonella</i> Biofilms; Royal Society of Chemistry, 2025; pp 160–188. doi:10.1039/9781837677047-00160
• Aggarwal, M.; Patra, A.; Awasthi, I.; George, A.; Gagneja, S.; Gupta, V.; Capalash, N.; Sharma, P. Drug repurposing against antibiotic resistant bacterial pathogens. European journal of medicinal chemistry 2024, 279, 116833. doi:10.1016/j.ejmech.2024.116833
• Guo, C.; Wang, K.-K. A.; Nolan, E. M. Investigation of Siderophore-Platinum(IV) Conjugates Reveals Differing Antibacterial Activity and DNA Damage Depending on the Platinum Cargo. ACS infectious diseases 2024, 10, 1250–1266. doi:10.1021/acsinfecdis.3c00686
• Savelyeva, I. O.; Zhdanova, K. A.; Gradova, M. A.; Gradov, O. V.; Bragina, N. A. Cationic Porphyrins as Antimicrobial and Antiviral Agents in Photodynamic Therapy. Current issues in molecular biology 2023, 45, 9793–9822. doi:10.3390/cimb45120612
• Chen, E. R.; Wozniak, R. A. F. Reimagining the Past: A Future for Antibiotic Drug Discovery in Ophthalmology. Cornea 2023, 43, 1–5. doi:10.1097/ico.0000000000003391
• Bari, A. K.; Belalekar, T. S.; Poojary, A.; Rohra, S. Combination drug strategies for biofilm eradication using synthetic and natural agents in KAPE pathogens. Frontiers in cellular and infection microbiology 2023, 13, 1155699. doi:10.3389/fcimb.2023.1155699
• Kacsir, I.; Sipos, A.; Major, E.; Bajusz, N.; Bényei, A.; Buglyó, P.; Somsák, L.; Kardos, G.; Bai, P.; Bokor, É. Half-Sandwich Type Platinum-Group Metal Complexes of C-Glucosaminyl Azines: Synthesis and Antineoplastic and Antimicrobial Activities. Molecules (Basel, Switzerland) 2023, 28, 3058. doi:10.3390/molecules28073058
• Bansal, K. K.; Goyal, R.; Sharma, A.; Sharma, P. C.; Goyal, R. K. Repurposing of Drugs for the Treatment of Microbial Diseases. Drug Repurposing for Emerging Infectious Diseases and Cancer; Springer Nature Singapore, 2023; pp 347–394. doi:10.1007/978-981-19-5399-6_16
• Kacsir, I.; Sipos, A.; Kiss, T.; Major, E.; Bajusz, N.; Tóth, E.; Buglyó, P.; Somsák, L.; Kardos, G.; Bai, P.; Bokor, É. Half sandwich-type osmium, ruthenium, iridium and rhodium complexes with bidentate glycosyl heterocyclic ligands induce cytostasis in platinum-resistant ovarian cancer cells and bacteriostasis in Gram-positive multiresistant bacteria. Frontiers in chemistry 2023, 11, 1086267. doi:10.3389/fchem.2023.1086267
• Clerici, D. J.; Hahn da Silveira, C.; Iglesias, B. A.; Christ Vianna Santos, R. The first evidence of antibiofilm action of Proteus mirabilis with tetra-cationic porphyrins containing cisplatin by antimicrobial photodynamic therapy. Microbial pathogenesis 2022, 174, 105859. doi:10.1016/j.micpath.2022.105859
• Chowdhury, N.; Bagchi, A. A drug repurposing endeavor to discover a multi-targeting ligand against RhlR and LasR proteins from opportunistic human pathogen Pseudomonas aeruginosa. Journal of molecular modeling 2022, 28, 295. doi:10.1007/s00894-022-05301-w
• Jampilek, J. Drug repurposing to overcome microbial resistance. Drug discovery today 2022, 27, 2028–2041. doi:10.1016/j.drudis.2022.05.006
• Balázs, B.; Tóth, Z.; Kacsir, I.; Sipos, A.; Buglyó, P.; Somsák, L.; Bokor, É.; Kardos, G.; Bai, P. Targeting Multiresistant Gram-Positive Bacteria by Ruthenium, Osmium, Iridium and Rhodium Half-Sandwich Type Complexes With Bidentate Monosaccharide Ligands. Frontiers in chemistry 2022, 10, 868234. doi:10.3389/fchem.2022.868234
• Pecoraro, C.; Carbone, D.; Deng, D.; Cascioferro, S. M.; Diana, P.; Giovannetti, E. Biofilm Formation as Valuable Target to Fight against Severe Chronic Infections. Current medicinal chemistry 2022, 29, 4307–4310. doi:10.2174/0929867329666220103095551
• Vyas, T.; Rapalli, V. K.; Chellappan, D. K.; Dua, K.; Dubey, S. K.; Singhvi, G. Bacterial biofilms associated skin disorders: Pathogenesis, advanced pharmacotherapy and nanotechnology-based drug delivery systems as a treatment approach. Life sciences 2021, 287, 120148. doi:10.1016/j.lfs.2021.120148
• Foletto, V. S.; da Rosa, T. F.; Serafin, M. B.; Bottega, A.; Hörner, R. Repositioning of non-antibiotic drugs as an alternative to microbial resistance: a systematic review. International journal of antimicrobial agents 2021, 58, 106380. doi:10.1016/j.ijantimicag.2021.106380
• Possato, B.; Dalmolin, L. F.; Pereira, L. M.; Alves, J. Q.; Silva, R. T. C.; Gelamo, R. V.; Yatsuda, A. P.; Lopez, R. F. V.; de Albuquerque, S.; Leite, N. B.; Maia, P. I. S. Gold(III) complexes with thiosemicarbazonate ligands as potential anticancer agents: Cytotoxicity and interactions with biomolecular targets. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2021, 162, 105834. doi:10.1016/j.ejps.2021.105834

Explore citations to this article at